GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generex Biotechnology Corp (OTCPK:GNBTQ) » Definitions » Piotroski F-Score

Generex Biotechnology (Generex Biotechnology) Piotroski F-Score : 0 (As of May. 22, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Generex Biotechnology Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Generex Biotechnology has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Generex Biotechnology's Piotroski F-Score or its related term are showing as below:


Generex Biotechnology Piotroski F-Score Historical Data

The historical data trend for Generex Biotechnology's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generex Biotechnology Piotroski F-Score Chart

Generex Biotechnology Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 3.00 5.00 3.00 3.00

Generex Biotechnology Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 3.00 2.00 1.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Apr21) TTM:Last Year (Apr20) TTM:
Net Income was -11.673 + -10.731 + -24.081 + 9.223 = $-37.26 Mil.
Cash Flow from Operations was -0.634 + -1.336 + -0.98 + 0.577 = $-2.37 Mil.
Revenue was 0.584 + 0.088 + 0 + 0.021 = $0.69 Mil.
Gross Profit was 0.419 + 0.065 + -0.105 + -0.045 = $0.33 Mil.
Average Total Assets from the begining of this year (Apr20)
to the end of this year (Apr21) was
(51.895 + 45.383 + 45.885 + 45.51 + 45.923) / 5 = $46.9192 Mil.
Total Assets at the begining of this year (Apr20) was $51.90 Mil.
Long-Term Debt & Capital Lease Obligation was $0.65 Mil.
Total Current Assets was $2.47 Mil.
Total Current Liabilities was $64.07 Mil.
Net Income was -4.786 + -9.126 + -6.91 + -5.626 = $-26.45 Mil.

Revenue was -0.051 + 0.722 + 0.857 + 0.499 = $2.03 Mil.
Gross Profit was -0.042 + 0.588 + 0.692 + 0.382 = $1.62 Mil.
Average Total Assets from the begining of last year (Apr19)
to the end of last year (Apr20) was
(54.036 + 49.636 + 52.24 + 52.103 + 51.895) / 5 = $51.982 Mil.
Total Assets at the begining of last year (Apr19) was $54.04 Mil.
Long-Term Debt & Capital Lease Obligation was $0.56 Mil.
Total Current Assets was $2.09 Mil.
Total Current Liabilities was $39.71 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Generex Biotechnology's current Net Income (TTM) was -37.26. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Generex Biotechnology's current Cash Flow from Operations (TTM) was -2.37. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Apr20)
=-37.262/51.895
=-0.71802678

ROA (Last Year)=Net Income/Total Assets (Apr19)
=-26.448/54.036
=-0.48945148

Generex Biotechnology's return on assets of this year was -0.71802678. Generex Biotechnology's return on assets of last year was -0.48945148. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Generex Biotechnology's current Net Income (TTM) was -37.26. Generex Biotechnology's current Cash Flow from Operations (TTM) was -2.37. ==> -2.37 > -37.26 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Apr21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Apr20 to Apr21
=0.654/46.9192
=0.01393886

Gearing (Last Year: Apr20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Apr19 to Apr20
=0.56/51.982
=0.01077296

Generex Biotechnology's gearing of this year was 0.01393886. Generex Biotechnology's gearing of last year was 0.01077296. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Apr21)=Total Current Assets/Total Current Liabilities
=2.469/64.074
=0.03853357

Current Ratio (Last Year: Apr20)=Total Current Assets/Total Current Liabilities
=2.093/39.713
=0.05270315

Generex Biotechnology's current ratio of this year was 0.03853357. Generex Biotechnology's current ratio of last year was 0.05270315. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Generex Biotechnology's number of shares in issue this year was 140.407. Generex Biotechnology's number of shares in issue last year was 76.977. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.334/0.693
=0.48196248

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.62/2.027
=0.79921066

Generex Biotechnology's gross margin of this year was 0.48196248. Generex Biotechnology's gross margin of last year was 0.79921066. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Apr20)
=0.693/51.895
=0.01335389

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Apr19)
=2.027/54.036
=0.03751203

Generex Biotechnology's asset turnover of this year was 0.01335389. Generex Biotechnology's asset turnover of last year was 0.03751203. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Generex Biotechnology has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Generex Biotechnology  (OTCPK:GNBTQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Generex Biotechnology Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Generex Biotechnology's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Generex Biotechnology (Generex Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
10102 USA Today Way, Miramar, FL, USA, 33025
Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.
Executives
Prioletti Mark Joseph Se director 1121 PALMER COURT CRYSTAL LAKE IL 60014
Salvo Lawrence Anthony Sr director 450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139
Harold Gray Haines other: Consultant 11511 SW 127TH ST MIAMI FL 33176
Mark Fletcher officer: EVP General Counsel &Secretary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Brian Mcgee director 201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000
Anderson James H Jr. director 33 HARBOUR SQUARE TORONTO A6 M5J2G2
Mark Corrao officer: CFO & Treasurer 531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825
Purcell Richard David Jr. director, officer: SVP of Research & Drug Develop 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
Gary Herbert Lyman director 10102 USA TODAY WAY MIRAMAR FL 33025
Kevin Centofanti director 10102 USA TODAY WAY MIRAMAR FL 33025
Andrew Ro director, officer: SVP & Chief Investment Officer 10102 USA TODAY WAY MIRAMAR FL 33025
David Brusegard officer: Chief Operating Officer 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Stephen Fellows officer: Chief Financial Officer 33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2
Hofe Eric Von director, officer: President of Subsidiary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
John P Barratt director 555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1

Generex Biotechnology (Generex Biotechnology) Headlines

From GuruFocus